Holger Eidtmann
Overview
Explore the profile of Holger Eidtmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
7608
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heppner B, Untch M, Denkert C, Pfitzner B, Lederer B, Schmitt W, et al.
Clin Cancer Res
. 2016 May;
22(23):5747-5754.
PMID: 27189162
Purpose: We elucidated the value of tumor-infiltrating lymphocytes (TIL) as an independent predictor for pathologic complete response (pCR) rate and as a prognostic marker for disease-free survival (DFS) in patients...
2.
Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al.
Lancet Oncol
. 2016 Feb;
17(3):345-356.
PMID: 26869049
Background: In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based paclitaxel. The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the...
3.
Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, et al.
Clin Cancer Res
. 2016 Jan;
22(11):2675-83.
PMID: 26758558
Background: The PI3K/AKT pathway and phosphatase and tensin homolog (PTEN) aberrations are common in breast cancer. We investigated the correlation between phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), PTEN, p4EBP1 (phosphorylated...
4.
Marme F, Lederer B, Blohmer J, Costa S, Denkert C, Eidtmann H, et al.
Eur J Cancer
. 2015 Dec;
53:65-74.
PMID: 26693900
Background: Pathologic complete response after neoadjuvant chemotherapy (NACT) correlates with overall survival (OS) in primary breast cancer. A recently described staging system based on pre-treatment clinical stage (CS), final pathological...
5.
Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck A, Viale G, et al.
J Clin Oncol
. 2015 Nov;
34(10):1034-42.
PMID: 26598744
Background: Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2-positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role...
6.
Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P, et al.
JAMA Oncol
. 2015 Jul;
1(4):448-54.
PMID: 26181252
Importance: The presence of tumor-infiltrating lymphocytes (TILs) is associated with improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer treated with adjuvant trastuzumab and chemotherapy. The...
7.
von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, et al.
Cancer
. 2015 Jun;
121(20):3639-48.
PMID: 26111104
Background: Although greater than 40% of breast cancers occur in patients aged ≥65 years, these individuals are frequently undertreated. Taxane-based adjuvant chemotherapy is considered the treatment of choice but to...
8.
Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kummel S, et al.
Breast Cancer Res Treat
. 2015 Jun;
152(2):377-87.
PMID: 26109347
Young women with breast cancer (BC) have a worse survival partly due to more aggressive tumor characteristics; however, their response to chemotherapy seems better. We investigated to what extent the...
9.
Hein A, Lambrechts D, von Minckwitz G, Haberle L, Eidtmann H, Tesch H, et al.
Int J Cancer
. 2015 Jun;
137(12):2981-8.
PMID: 26100253
Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different effects on progression-free and overall survival, suggesting that a subgroup of patients may benefit from...
10.
Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kummel S, et al.
Clin Cancer Res
. 2015 Apr;
21(13):2924-31.
PMID: 25825476
Purpose: Dual anti-HER2 blockade with trastuzumab/pertuzumab or trastuzumab/lapatinib in combination with anthracycline/taxane-based chemotherapy can reach pathologic complete response (pCR) rates of up to 60% in HER2-positive breast cancer. The DAFNE...